Filtered By:
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 7481 results found since Jan 2013.
Insomnia Management: A Review and Update
J Fam Pract. 2023 Jul;72(6 Suppl):S31-S36. doi: 10.12788/jfp.0620.ABSTRACTInsomnia is a distinct disorder that is common, yet underrecognized and undertreated in primary care. Treating insomnia has been shown to improve outcomes, including reduced risk of developing cardiovascular and mental health disorders. Insomnia is influenced by the brain's regulation of sleep and wake, which are mutually exclusive events. Insomnia should be treated as a distinct condition, even when occurring with a comorbid diagnosis such as depression or anxiety. Clinicians should implement a multimodal approach to insomnia management, including n...
Source: The Journal of Family Practice - August 7, 2023 Category: Practice Management Authors: David P Shaha Source Type: research
Use of ICS and Fast-Acting Bronchodilators in Asthma: Past, Present, and Future
J Fam Pract. 2023 Jul;72(6 Suppl):S61-S70. doi: 10.12788/jfp.0625.ABSTRACTPrimary care practitioners (PCPs) play a key role in asthma management since most patients with asthma are treated in primary care settings. Despite continual advances in asthma care, important practice gaps remain, and the high burden of asthma exacerbations persists, with 43% of children with asthma and 41% of adults with asthma in the United States experiencing an asthma exacerbation in 2020. Uncontrolled asthma, incomplete assessment of exacerbation and asthma control history, reliance on systemic corticosteroids (SCS) or short-acting beta2-agoni...
Source: The Journal of Family Practice - August 7, 2023 Category: Practice Management Authors: Neil Skolnik Marissa Norden Njira Lugogo Wendy Wright Source Type: research
Insomnia Management: A Review and Update
J Fam Pract. 2023 Jul;72(6 Suppl):S31-S36. doi: 10.12788/jfp.0620.ABSTRACTInsomnia is a distinct disorder that is common, yet underrecognized and undertreated in primary care. Treating insomnia has been shown to improve outcomes, including reduced risk of developing cardiovascular and mental health disorders. Insomnia is influenced by the brain's regulation of sleep and wake, which are mutually exclusive events. Insomnia should be treated as a distinct condition, even when occurring with a comorbid diagnosis such as depression or anxiety. Clinicians should implement a multimodal approach to insomnia management, including n...
Source: The Journal of Family Practice - August 7, 2023 Category: Practice Management Authors: David P Shaha Source Type: research
Tetracycline antibiotics: Potential anticancer drugs
Eur J Pharmacol. 2023 Aug 2:175949. doi: 10.1016/j.ejphar.2023.175949. Online ahead of print.ABSTRACTIn recent years, research on tetracycline antibiotics has gradually shifted from their antibacterial effects to anticancer effects. Doxycycline, minocycline, and tigecycline as the US Food and Drug Administration (FDA) approved tetracycline antibiotics have been the main subjects of studies. Evidence indicated that they have anticancer properties and are able to control cancer progression through different mechanisms, such as anti-proliferation, anti-metastasis, and promotion of autophagy or apoptosis. In addition, studies ...
Source: European Journal of Pharmacology - August 4, 2023 Category: Drugs & Pharmacology Authors: Jiayu Li Yuan Qin Chenhao Zhao Zhi Zhang Zhiruo Zhou Source Type: research
Anticancer clinical efficiency and stochastic mechanisms of belinostat
Biomed Pharmacother. 2023 Aug 1;165:115212. doi: 10.1016/j.biopha.2023.115212. Online ahead of print.ABSTRACTCancer progression is strongly affected by epigenetic events in addition to genetic modifications. One of the key elements in the epigenetic control of gene expression is histone modification through acetylation, which is regulated by the synergy between histone acetyltransferases (HATs) and histone deacetylases (HDACs). HDACs are thought to offer considerable potential for the development of anticancer medications, particularly when used in conjunction with other anticancer medications and/or radiotherapy. Belinost...
Source: Cancer Control - August 4, 2023 Category: Cancer & Oncology Authors: Nasreddine El Omari Saad Bakrim Asaad Khalid Mohammed Albratty Ashraf N Abdalla Learn-Han Lee Khang Wen Goh Long Chiau Ming Abdelhakim Bouyahya Source Type: research
Tetracycline antibiotics: Potential anticancer drugs
Eur J Pharmacol. 2023 Aug 2:175949. doi: 10.1016/j.ejphar.2023.175949. Online ahead of print.ABSTRACTIn recent years, research on tetracycline antibiotics has gradually shifted from their antibacterial effects to anticancer effects. Doxycycline, minocycline, and tigecycline as the US Food and Drug Administration (FDA) approved tetracycline antibiotics have been the main subjects of studies. Evidence indicated that they have anticancer properties and are able to control cancer progression through different mechanisms, such as anti-proliferation, anti-metastasis, and promotion of autophagy or apoptosis. In addition, studies ...
Source: European Journal of Pharmacology - August 4, 2023 Category: Drugs & Pharmacology Authors: Jiayu Li Yuan Qin Chenhao Zhao Zhi Zhang Zhiruo Zhou Source Type: research
Anticancer clinical efficiency and stochastic mechanisms of belinostat
Biomed Pharmacother. 2023 Aug 1;165:115212. doi: 10.1016/j.biopha.2023.115212. Online ahead of print.ABSTRACTCancer progression is strongly affected by epigenetic events in addition to genetic modifications. One of the key elements in the epigenetic control of gene expression is histone modification through acetylation, which is regulated by the synergy between histone acetyltransferases (HATs) and histone deacetylases (HDACs). HDACs are thought to offer considerable potential for the development of anticancer medications, particularly when used in conjunction with other anticancer medications and/or radiotherapy. Belinost...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - August 4, 2023 Category: Drugs & Pharmacology Authors: Nasreddine El Omari Saad Bakrim Asaad Khalid Mohammed Albratty Ashraf N Abdalla Learn-Han Lee Khang Wen Goh Long Chiau Ming Abdelhakim Bouyahya Source Type: research
Structural-Based Virtual Screening of FDA-Approved Drugs Repository for NSP16 Inhibitors, Essential for SARS-COV-2 Invasion Into Host Cells: Elucidation From MM/PBSA Calculation
Bioinform Biol Insights. 2023 Jul 31;17:11779322231171777. doi: 10.1177/11779322231171777. eCollection 2023.ABSTRACTNSP16 is one of the structural proteins of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) necessary for its entrance to the host cells. It exhibits 2'O-methyl-transferase (2'O-MTase) activity of NSP16 using methyl group from S-adenosyl methionine (SAM) by methylating the 5-end of virally encoded mRNAs and shields viral RNA, and also controls its replication as well as infection. In the present study, we used in silico approaches of drug repurposing to target and inhibit the SAM binding site ...
Source: Bioinformatics and Biology Insights - August 3, 2023 Category: Bioinformatics Authors: Subodh Kumar Harvinder Singh Manisha Prajapat Phulen Sarma Anusuya Bhattacharyya Hardeep Kaur Gurjeet Kaur Nishant Shekhar Karanveer Kaushal Kalpna Kumari Seema Bansal Saniya Mahendiratta Arushi Chauhan Ashutosh Singh Rahul Soloman Singh Saurabh Sharma Pr Source Type: research
